Nastech Appoints MDRNA, Inc. Directors Strategic Advisory Board
05 Febrero 2008 - 7:00AM
PR Newswire (US)
BOTHELL, Wash., Feb. 5 /PRNewswire-FirstCall/ -- Nastech
Pharmaceutical Company Inc. ("Nastech") (NASDAQ:NSTK) announced
today that it has named members to the MDRNA, Inc. ("MDRNA")
Directors Strategic Advisory Board that will provide scientific,
financial and corporate governance expertise as Nastech moves to
establish MDRNA, currently a wholly-owned subsidiary, as an
independent company. Advisory Board appointees include: Susan B.
Bayh, J.D. has been a director of Nastech since July 2005 as a
member of the Compensation and chairman of the Nominating and
Corporate Governance Committees of the Board of Directors. Mrs.
Bayh currently serves on the boards of directors of Curis, Inc., a
therapeutic drug development company, Dendreon Corporation, a
therapeutic drug development company, Dyax Corp., a
biopharmaceutical company, Emmis Communications, a diversified
media company, and Wellpoint, Inc., a Blue Cross / Blue Shield
company. In addition, Mrs. Bayh is a member of the Audit and
Compensation Committees of the board of directors of Curis, Inc.,
and a member of the Compensation Committee of the board of
directors of Emmis Communications. Previously, Mrs. Bayh also
served on the boards of directors of Cubist Pharmaceuticals, Inc.,
a pharmaceutical company, from 2000 to 2004, and Esperion
Therapeutics, Inc., a biopharmaceutical company, from 2000 to 2003.
From 1994 to 2004, she was a Distinguished Visiting Professor at
the College of Business Administration at Butler University in
Indianapolis, Indiana. From 1994 to 2000, she was a Commissioner
for the International Joint Commission of the Water Treaty Act
between the United States and Canada. From 1989 to 1994, Mrs. Bayh
served as an attorney in the Pharmaceutical Division of Eli Lilly
and Company. Mrs. Bayh earned a Bachelor of Arts degree from the
University of California at Berkeley and received her J.D. degree
from the University of Southern California Law Center. Alexander D.
Cross, Ph.D. has been a director of Nastech since July 2005 and is
currently chairman of the Audit and a member of the Nominating and
Corporate Governance Committees of the Board of Directors. Dr.
Cross served on the board of directors of Ligand Pharmaceuticals
Inc. and was a member of its Audit and Compensation Committees
until March 2007. Dr. Cross also served as Chairman of the Board
and Chief Executive Officer of Cytopharm, Inc. until August 2006.
Dr. Cross has been a consultant in the fields of pharmaceuticals
and biotechnology since January 1986 and is presently a principal
of NDA Partners. Previously, Dr. Cross served as President and
Chief Executive Officer of Zoecon Corporation, a biotechnology
company, from April 1983 to December 1985, and Executive Vice
President and Chief Operating Officer from 1979 to 1983. Dr. Cross
also previously held several corporate management positions at
Syntex Corporation from 1961 through 1979. Dr. Cross holds 109
issued United States patents and is the author of 90 peer-reviewed
publications. Dr. Cross received his B.Sc., Ph.D. and D.Sc. degrees
from the University of Nottingham, England, and is a Fellow of the
Royal Society of Chemistry. Daniel L. Peters was most recently
President and CEO of global Medical Diagnostics at GE Healthcare.
Prior to his role at GE Healthcare, Mr. Peters was Chief Operating
Officer at Amersham Health. Previously, he served as the President
of Nycomed Amersham Imaging, where he was responsible for managing
the company's diagnostic pharmaceutical operations in North, South,
and Central America. Mr. Peters had been President of Nycomed
Imaging Inc. in the Americas from 1994 to 1997. Prior to that, he
held roles of increasing responsibility within the U.S.
pharmaceuticals business of Sterling Winthrop including marketing,
strategic planning and general management, being appointed
President of the U.S. Pharmaceutical business in 1993. Mr. Peters
is a former Trustee and founding member of the Health Care
Institute of New Jersey from 1996 to 2006; a former board member of
the Pharmaceutical Research and Manufacturers of America from 1995
to 2005 and a former board member of the National Pharmaceutical
Council from 1990 to 1993. Mr. Peters also served on the board of
Diatide Inc. from 1994 to 1997. Mr. Peters holds a bachelors degree
from Western Illinois University. Steven C. Quay, M.D., Ph.D., has
been employed by Nastech since August 2000 and currently serves as
the Chairman of the Board and CEO. In 1999, Dr. Quay founded and
was Chairman, President and CEO of Atossa Healthcare, Inc., which
focused on the development of a proprietary platform of diagnostics
and treatments related to breast cancer risk assessment and
therapeutics and other healthcare products for women. Nastech
acquired Atossa in August 2000. In 1991, Dr. Quay founded Sonus
Pharmaceuticals, Inc., a company engaged in the research and
development of drug delivery systems and oxygen delivery products
based on emulsion and surfactant technology, where he served as
CEO, President and a director until June 1999. In 1984, Dr. Quay
founded Salutar, Inc. to develop contrast agents for magnetic
resonance imaging. Two pharmaceuticals, OmniScan(R) and
TeslaScan(R), were invented by Dr. Quay at Salutar and have been
used in over 35 million patients since the drugs received
regulatory approval. Dr. Quay has authored more than 100 papers in
diagnostic imaging, oncology, RNA interference and biochemistry and
holds 65 U.S. patents. Dr. Quay graduated from the University of
Michigan Medical School, where he received an M.A. and a Ph.D. in
biological chemistry in 1974 and 1975, respectively, and an M.D. in
1977. Dr. Quay completed his post-graduate work in the chemistry
department of Massachusetts Institute of Technology and received
his residency training at Massachusetts General Hospital, Harvard
Medical School in Boston. From 1980 to 1986, he was a faculty
member of Stanford University School of Medicine. James E. Rothman,
Ph.D., is currently the Clyde and Helen Wu Professor of Chemical
Biology and Director of Columbia University's Judith P. Sulzberger,
M.D. Genome Center. Until December 2007, Rothman served as the
Chief Science Advisor of GE Healthcare. He elucidated the molecular
machinery responsible for the transfer of materials among
compartments within cells. Prior to joining Columbia University in
2004, Professor Rothman held Professorships at Stanford (1978-1988)
and Princeton (1988-1991) universities. In 1991, he founded the
Cellular Biochemistry and Biophysics Department at Memorial Sloan-
Kettering Cancer Center and was Vice-Chairman of Sloan-Kettering in
New York City (1991-2004). Professor Rothman's pioneering research
in cell biology has been recognized by the U.S. National Academy of
Sciences (1993). He has also received numerous international
awards, including the Albert Lasker Award for Basic Medical
Research in 2002. Gregory Sessler currently serves as the Chief
Financial Officer of Spiration, Inc. and is a director of VLST,
Corp. Prior to joining Spiration, Mr. Sessler served as Senior Vice
President and Chief Financial Officer of Rosetta Inpharmatics, a
leader in informational genomics, from March 2000 until its
acquisition by Merck & Co. in July 2001 for $540 million. In
addition to playing an instrumental role in the acquisition by
Merck, Mr. Sessler led Rosetta's efforts to a successful initial
public offering in August 2000 as well as previous initial public
offerings for three other biomedical companies. Mr. Sessler is a
member of the AICPA and the Financial Executives International and
previously served on the board of directors of Corixa Corporation.
He is also on the Executive Committee and past chairman of the
Board of Directors of the Washington Biotechnology and Biomedical
Association. Mr. Sessler holds a bachelor's degree, magna cum
laude, from Syracuse University and a M.B.A. from Stanford. Bruce
R. Thaw, J.D., has been a director of Nastech since June 1991 and
currently serves as member of the Audit and Compensation Committees
of the Board of Directors. Since January 2000, Mr. Thaw has served
as the President and Chief Executive Officer of Bulbtronics, Inc.,
a national distributor of technical and specialty light sources and
related products to the medical, scientific, entertainment and
industrial markets. Mr. Thaw is a practicing attorney and was
admitted to the bar of the State of New York in 1978 and the
California State Bar in 1983. From 1984 to 2001, Mr. Thaw served as
Nastech's general counsel. From 1990 until April 2007, Mr. Thaw
served as a member of the board of directors of SafeNet, Inc., a
company that designs, manufactures and markets information security
systems, products and services that protect and secure digital
identities, communications, intellectual property and applications
over wide area networks and virtual private networks. Mr. Thaw
holds a B.B.A. degree in Banking and Finance from Hofstra
University and a J.D. degree from the Hofstra University School of
Law. About Nastech Nastech is a biopharmaceutical company
developing innovative products based on proprietary molecular
biology-based drug delivery technologies. Nastech is creating
technologies that enable the delivery of peptide and protein
therapeutics without the requirement of an injection, which is
currently the most common form of administration for this class of
drugs. Nastech has also established a wholly-owned subsidiary,
MDRNA, Inc., to focus on developing RNA-based technologies and
therapeutics. MDRNA is harnessing the power of RNA interference, a
cellular mechanism that can turn off the production of a specific
protein through use of small interfering RNAs (siRNAs), to develop
a new class of therapeutics by identifying key protein targets,
designing the siRNAs that will turn off the production of the
targeted proteins, and creating a formulation for the delivery of
the therapeutics. Nastech and its collaboration partners are
developing products for multiple therapeutic areas including
osteoporosis, obesity, diabetes, autism, respiratory diseases and
inflammatory conditions. For additional information about Nastech
please visit http://www.nastech.com/. Nastech Forward Looking
Statements Statements made in this press release may be
forward-looking statements within the meaning of Federal Securities
laws that are subject to certain risks and uncertainties and
involve factors that may cause actual results to differ materially
from those projected or suggested. Factors that could cause actual
results to differ materially from those in forward-looking
statements include, but are not limited to: (i) the ability of
Nastech or a subsidiary to obtain additional funding; (ii) the
ability of Nastech or a subsidiary to attract and/or maintain
manufacturing, research, development and commercialization
partners; (iii) the ability of Nastech, a subsidiary and/or a
partner to successfully complete product research and development,
including preclinical and clinical studies and commercialization;
(iv) the ability of Nastech, a subsidiary and/or a partner to
obtain required governmental approvals; and (v) the ability of
Nastech, a subsidiary and/or a partner to develop and commercialize
products that can compete favorably with those of competitors.
Additional factors that could cause actual results to differ
materially from those projected or suggested in any forward-looking
statements are contained in Nastech's most recent periodic reports
on Form 10-K and Form 10-Q that are filed with the Securities and
Exchange Commission. Nastech assumes no obligation to update and
supplement forward-looking statements because of subsequent events.
Contacts: Nastech Bruce York Secretary and Interim Chief Financial
Officer (425) 908-3698 Russo Partners, LLC David Schull (Media)
(212) 845-4271 DATASOURCE: Nastech Pharmaceutical Company Inc.
CONTACT: Bruce York, Secretary and Interim Chief Financial Officer,
Nastech, +1-425-908-3698, , or Media, David Schull, Russo Partners,
LLC, +1-212-845-4271 Web site: http://www.nastech.com/
Copyright
Nastech Pharmaceutical Company (MM) (NASDAQ:NSTK)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Nastech Pharmaceutical Company (MM) (NASDAQ:NSTK)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024